Back to Journals » International Journal of Women's Health » Volume 2

The use of anti-TNFα medications for rheumatologic disease in pregnancy

Authors Clowse M

Published 29 June 2010 Volume 2010:2 Pages 199—209

DOI https://doi.org/10.2147/IJWH.S6029

Review by Single-blind

Peer reviewer comments 2


Megan EB Clowse

Division of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, NC, USA

Abstract: Anti-TNFα medications have led to vast improvements in the treatment of inflammatory conditions, including rheumatoid arthritis and Crohn’s disease. As these diseases often afflict women in their reproductive years, the safety of these drugs during pregnancy is an important issue. Prospectively collected data thus far appear to be reassuring; however an analysis of the FDA-reported anomalies has raised some questions. It appears that significant levels of these drugs cross the placenta as the pregnancy nears term, but little is passed through breast milk. Prior to using these medications during pregnancy, the risks and benefits of these drugs, other treatment options, and the ongoing inflammatory condition all must be carefully weighed by both doctor and patient.
Keywords: pregnancy, anti-TNFα medications, rheumatoid arthritis, Crohn’s disease, teratogenesis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]